MCID: MSC007
MIFTS: 58

Muscle Hypertrophy

Categories: Genetic diseases, Rare diseases, Muscle diseases

Aliases & Classifications for Muscle Hypertrophy

MalaCards integrated aliases for Muscle Hypertrophy:

Name: Muscle Hypertrophy 57 75 29 13 6 40
Hypertrophy 44 73
Mslhp 57 75
Myostatin-Related Muscle Hypertrophy 59

Characteristics:

Orphanet epidemiological data:

59
myostatin-related muscle hypertrophy
Inheritance: Autosomal recessive; Age of onset: Infancy,Neonatal;

HPO:

32
muscle hypertrophy:
Inheritance autosomal recessive inheritance


Classifications:



External Ids:

OMIM 57 614160
Orphanet 59 ORPHA275534
UMLS via Orphanet 74 C2931112
SNOMED-CT via HPO 69 258211005
UMLS 73 C0020564

Summaries for Muscle Hypertrophy

UniProtKB/Swiss-Prot : 75 Muscle hypertrophy: A condition characterized by increased muscle bulk and strength. Affected individuals are exceptionally strong.

MalaCards based summary : Muscle Hypertrophy, also known as hypertrophy, is related to hypertrophic cardiomyopathy and myostatin-related muscle hypertrophy, and has symptoms including cachexia, cyanosis and dyspnea. An important gene associated with Muscle Hypertrophy is MSTN (Myostatin), and among its related pathways/superpathways are NFAT and Cardiac Hypertrophy and AMP-activated Protein Kinase (AMPK) Signaling. The drugs Acetylcholine and Lidocaine have been mentioned in the context of this disorder. Affiliated tissues include skeletal muscle, smooth muscle and bone, and related phenotypes are skeletal muscle hypertrophy and Decreased viability with paclitaxel

Wikipedia : 76 Muscle hypertrophy involves an increase in size of skeletal muscle through a growth in size of its... more...

Description from OMIM: 614160

Related Diseases for Muscle Hypertrophy

Diseases in the Muscle Hypertrophy family:

Myostatin-Related Muscle Hypertrophy

Diseases related to Muscle Hypertrophy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 74)
# Related Disease Score Top Affiliating Genes
1 hypertrophic cardiomyopathy 28.7 FHL1 IGF1 MYH6 MYH7
2 myostatin-related muscle hypertrophy 12.5
3 adenoid hypertrophy 12.3
4 masticatory muscles, hypertrophy of 12.2
5 myopathy, x-linked, with postural muscle atrophy 10.9
6 uruguay faciocardiomusculoskeletal syndrome 10.8 FHL1 MSTN
7 myhre syndrome 10.8
8 muscular dystrophy, congenital, 1b 10.8
9 muscular dystrophy-dystroglycanopathy , type b, 5 10.8
10 glucose intolerance 10.2 FOXO1 IGF1 LEP
11 sleep apnea 10.1 EDN1 IGF1 LEP
12 aging 10.0
13 central sleep apnea 10.0 LEP NPPA
14 muscular dystrophy 10.0
15 myopathy, distal, 1 9.9 MYH6 MYH7
16 myotonia 9.9
17 scapuloperoneal myopathy 9.9 FHL1 MYH6 MYH7
18 myosin storage myopathy 9.9 MYH6 MYH7
19 familial sick sinus syndrome 9.9 AGT MYH6
20 myotonia congenita 9.9
21 neuropathy 9.9
22 muscular dystrophy, becker type 9.8
23 muscular dystrophy, duchenne type 9.8
24 multifocal motor neuropathy 9.8
25 radiculopathy 9.8
26 hypoxia 9.8
27 hypoplastic left heart syndrome 9.7 LEP MYH6 NPPA
28 malignant hypertension 9.7 AGT EDN1 NPPA
29 arteries, anomalies of 9.7 AGT EDN1 LEP
30 aortic valve disease 2 9.7 AGT MYH7 NPPA
31 autosomal dominant polycystic kidney disease 9.6 AGT EDN1 IGF1 MTOR
32 myositis 9.6
33 myeloma, multiple 9.6
34 insulin-like growth factor i 9.6
35 esophagitis, eosinophilic, 1 9.6
36 pulmonary hypertension 9.6
37 crohn's disease 9.6
38 spinal muscular atrophy 9.6
39 cardiac arrest 9.6
40 cysticercosis 9.6
41 amyotrophic neuralgia 9.6
42 tethered spinal cord syndrome 9.6
43 mononeuropathy 9.6
44 esophagitis 9.6
45 entropion 9.6
46 tarsal tunnel syndrome 9.6
47 hypertrophic pyloric stenosis 9.6
48 pyloric stenosis 9.6
49 vertebrobasilar insufficiency 9.6
50 urethritis 9.6

Graphical network of the top 20 diseases related to Muscle Hypertrophy:



Diseases related to Muscle Hypertrophy

Symptoms & Phenotypes for Muscle Hypertrophy

Clinical features from OMIM:

614160

Human phenotypes related to Muscle Hypertrophy:

32
# Description HPO Frequency HPO Source Accession
1 skeletal muscle hypertrophy 32 HP:0003712

UMLS symptoms related to Muscle Hypertrophy:


cachexia, cyanosis, dyspnea, edema, fever, headache, hepatosplenomegaly, icterus, seizures, signs and symptoms, signs and symptoms, digestive, syncope, vertigo, hot flushes

GenomeRNAi Phenotypes related to Muscle Hypertrophy according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability with paclitaxel GR00179-A-1 9.02 IGF1 MTOR
2 Decreased viability with paclitaxel GR00179-A-2 9.02 IGF1 MTOR
3 Decreased viability with paclitaxel GR00179-A-3 9.02 MTOR

MGI Mouse Phenotypes related to Muscle Hypertrophy:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.34 AGT EDN1 FHL1 FOXO1 GATA6 IGF1
2 growth/size/body region MP:0005378 10.25 GATA6 HDAC4 IGF1 KLF15 LEP MEF2A
3 homeostasis/metabolism MP:0005376 10.21 AGT EDN1 FHL1 FOXO1 GATA6 IGF1
4 behavior/neurological MP:0005386 10.2 AGT FHL1 FOXO1 HDAC4 LEP MEF2A
5 mortality/aging MP:0010768 10.1 AGT EDN1 FOXO1 GATA6 HDAC4 IGF1
6 muscle MP:0005369 10.09 KLF15 LEP MEF2A MSTN MTOR MYH6
7 adipose tissue MP:0005375 10.02 AGT FOXO1 IGF1 KLF15 LEP MSTN
8 liver/biliary system MP:0005370 9.92 AGT FOXO1 GATA6 KLF15 LEP MSTN
9 normal MP:0002873 9.56 EDN1 FOXO1 GATA6 IGF1 MEF2A MTOR
10 renal/urinary system MP:0005367 9.28 AGT EDN1 IGF1 KLF15 LEP MSTN

Drugs & Therapeutics for Muscle Hypertrophy

Drugs for Muscle Hypertrophy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 52)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved Phase 4,Phase 2,Not Applicable 51-84-3 187
2
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
3 abobotulinumtoxinA Phase 4,Phase 2,Not Applicable
4 Botulinum Toxins Phase 4,Phase 2,Not Applicable
5 Botulinum Toxins, Type A Phase 4,Phase 2,Not Applicable
6 Cholinergic Agents Phase 4,Phase 2,Not Applicable
7 incobotulinumtoxinA Phase 4
8 Neuromuscular Agents Phase 4,Phase 2,Not Applicable
9 Neurotransmitter Agents Phase 4,Phase 2,Not Applicable
10 onabotulinumtoxinA Phase 4,Phase 2,Not Applicable
11 Peripheral Nervous System Agents Phase 4,Phase 2,Not Applicable
12 Anesthetics Phase 4
13 Anesthetics, Local Phase 4
14 Anti-Arrhythmia Agents Phase 4
15 Central Nervous System Depressants Phase 4
16 Diuretics, Potassium Sparing Phase 4
17 Sodium Channel Blockers Phase 4
18
Creatine Approved, Investigational, Nutraceutical Phase 3 57-00-1 586
19 Liver Extracts Phase 3,Not Applicable
20
Ethanol Approved Phase 2 64-17-5 702
21 insulin Phase 2,Not Applicable
22 Insulin, Globin Zinc Phase 2,Not Applicable
23 Pharmaceutical Solutions Phase 2,Not Applicable
24
Adenosine Approved, Investigational Not Applicable 58-61-7 60961
25
Menthol Approved Not Applicable 2216-51-5 16666
26
Clenbuterol Approved, Investigational, Vet_approved Not Applicable 37148-27-9 2783
27
Terbutaline Approved Not Applicable 23031-25-6 5403
28
Benzocaine Approved, Investigational Not Applicable 1994-09-7, 94-09-7 2337
29
Testosterone Approved, Investigational Not Applicable 58-22-0 6013
30
Glycine Approved, Nutraceutical, Vet_approved Not Applicable 56-40-6 750
31 tannic acid Approved, Nutraceutical Not Applicable
32 Adrenergic Agents Not Applicable
33 Adrenergic Agonists Not Applicable
34 Adrenergic beta-2 Receptor Agonists Not Applicable
35 Adrenergic beta-Agonists Not Applicable
36 Albuterol Not Applicable
37 Anti-Asthmatic Agents Not Applicable
38 Autonomic Agents Not Applicable
39 Bronchodilator Agents Not Applicable
40 Respiratory System Agents Not Applicable
41 Tocolytic Agents Not Applicable
42 Caseins Not Applicable
43 Calcium, Dietary Not Applicable
44 Chelating Agents Not Applicable
45 Androgens Not Applicable
46 Hormone Antagonists Not Applicable
47 Hormones Not Applicable
48 Hormones, Hormone Substitutes, and Hormone Antagonists Not Applicable
49 Estrogens Not Applicable
50 beta-Hydroxy-beta-methylbutyrate Nutraceutical Not Applicable

Interventional clinical trials:

(show top 50) (show all 58)
# Name Status NCT ID Phase Drugs
1 Xeomin Cosmetic in the Management of Masseter Completed NCT03376464 Phase 4
2 Efficacy of Botulinum Toxin Versus Lidocaine in Treating Masticatory Myofascial Face Pain Using Ultrasound and EMG Guided Techniques Terminated NCT00992108 Phase 4 lidocaine;chemodenervation
3 Effectiveness of Creatine Supplementation and Exercise on Muscle and Bone Completed NCT01057680 Phase 3
4 Effects of Kneehab 12-week Peri-operative Total Knee Arthroplasty Completed NCT01096524 Phase 3
5 MEDITOXIN® Treatment in Subject With Benign Masseteric Hypertrophy Not yet recruiting NCT03452345 Phase 3 Meditoxin;Placebo
6 Egg Cholesterol Consumption, Blood Cholesterol and Skeletal Muscle Hypertrophy Unknown status NCT00260442 Phase 2
7 Botulinum Toxin Type A (BOTOX®) Treatment of Masseter Muscle Hypertrophy Completed NCT02010775 Phase 2 Normal saline
8 The Effect of Neuromuscular Electrical Stimulation (NMES) Completed NCT00765739 Phase 2
9 Treatment of Temporo-Myofascial Disorder of Muscular Origin Using Botulinum Toxin: A Prospective Study Not yet recruiting NCT02810015 Phase 2 Botulinum Toxin Type A
10 Exercise and Nutrition Interventions in Age-related Sarcopenia Recruiting NCT02912130 Phase 1
11 Characterization of the Changes in the Signalling Pathways During Spinal Cord Injury-induced Skeletal Muscle Atrophy Unknown status NCT01470950 Not Applicable
12 Pascal Pascal Dynamic Contour Tonometer (DCT) Intraocular Pressure and Ocular Pulse Amplitude in Patients With Thyroid Related Orbitopathy: A Comparison to Goldmann Tonometer and to Muscles Characteristics on CT Scan Unknown status NCT00646295 Not Applicable
13 Chronic Beta2-adrenergic Stimulation and Cardiac and Skeletal Muscle Hypertrophy Completed NCT02551276 Not Applicable Salbutamol;Placebo
14 Maximizing Mechanisms of Muscle Hypertrophy to Combat Sarcopenia in Older Adults Completed NCT02442479 Not Applicable
15 Leucine or Protein Supplementation and Resistance Training Completed NCT03501628 Not Applicable
16 Effectiveness of NMES Associated to Vascular Occlusion in Functional Performance and Muscle Hypertrophy in Athlete's Completed NCT02406339 Not Applicable
17 The Effects of Lifting Light or Heavy Weights on Muscle Growth and Strength in Trained Young Men Completed NCT02139865 Not Applicable
18 The Effect of Insect Protein on Performance and Hypertrophy Completed NCT03034239 Not Applicable
19 The Effects of HMB, ATP, and HMB Plus ATP on Muscle Mass, Strength, and Power in Resistance Trained Athletes Completed NCT01508338 Not Applicable
20 Post-exercise Recovery After Dietary Protein Ingestion in Healthy Young Men (Meat-Milk Study) Completed NCT01578590 Not Applicable
21 Protein Nutrition for Muscle Hypertrophy in Older Adults Completed NCT02315391 Not Applicable
22 Comparison of 1 vs 3 Sets of Resistance Training on Muscular Hypertrophy Completed NCT01107691 Not Applicable
23 Overeating Different Fats and Influence on Muscle Mass and Body Fat Accumulation Completed NCT02211612 Not Applicable
24 Whole Milk Versus Whey Protein Supplement and Resistance Exercise Completed NCT01580189 Not Applicable
25 The Use of Neuromuscular Electrical Stimulation to Reverse Muscle Atrophy in Patients With Rheumatoid Arthritis Completed NCT00924625 Not Applicable
26 Effects of Native Whey or Milk Supplementation on Adaptations to 12 Weeks of Strength Training in Young and Elderly Completed NCT03033953 Not Applicable
27 Protein Supply in Elderly Completed NCT01317511 Not Applicable
28 Electrostimulation, Skeletal Muscle Function, and Exercise Capacity in Chronic Obstructive Pulmonary Disease (COPD) Completed NCT00874965 Not Applicable
29 HIV Posterior Cheek Enlargement Completed NCT01635504 Not Applicable
30 Get in Shape in the Team Research: Porukalla Kuntoon Tutkimus Completed NCT02413112 Not Applicable
31 Postprandial Muscle Protein Synthesis Following Wheat Protein Ingestion in Vivo in Humans Completed NCT01952639 Not Applicable
32 Exercise Intermittent Isometric Handgrip and Blood Flow Restriction Completed NCT02384161 Not Applicable
33 Descriptive Study of Knee Joint Pain During Strength Training After Total Knee Arthroplasty Completed NCT01729520 Not Applicable
34 Muscle MRI in Becker Muscular Dystrophy and in Limb-girdle Muscular Dystrophy Type 2I Completed NCT02165358
35 Individual Response to Different Volumes of Resistance Training Completed NCT02179307 Not Applicable
36 Effects of Resistance Training on Physical Performance, Health and Quality of Life in Elderly (RTCHealth) Completed NCT03551132 Not Applicable
37 High Intensity Interval Training or Strength Training in Women With Polycystic Ovary Syndrome Completed NCT01919281 Not Applicable
38 Effective Training in Overweight and Obese People Completed NCT00218920 Not Applicable
39 Effects of Casein Timing on Body Composition and Performance Completed NCT03352583 Not Applicable
40 DAHANCA 25B: Progressive Resistance Training as Intervention for Regaining Muscle Mass After Radiation Therapy in Patients With HNSCC Completed NCT01509430 Not Applicable
41 Skeletal Muscle Hypertrophy and Cardio-Metabolic Benefits After Spinal Cord Injury Recruiting NCT02660073 Not Applicable
42 cAMP Signaling and Muscle Adaptations Recruiting NCT02557581 Not Applicable Terbutaline;Clenbuterol;Placebo
43 Blood Flow Restriction Training in Patients With Weight Bearing Restrictions After Knee Surgery Recruiting NCT03371901 Not Applicable
44 Low Intensity Resistance Training With Vascular Occlusion in Coronary Heart Disease Patients Recruiting NCT03087292 Not Applicable
45 Physical Therapy for Anal Incontinence Recruiting NCT03252951 Not Applicable
46 Upper- and Lower-body Resistance Exercise With and Without Blood Flow Restriction on Hemodynamics and Vascular Function Recruiting NCT03225898 Not Applicable
47 Activity Dependent Rehabilitation Model to Improve Bone and Muscle Outcomes Recruiting NCT02309983 Not Applicable
48 Time-Restricted Feeding Plus Resistance Training in Active Females Recruiting NCT03404271 Not Applicable
49 Concurrent Training in Type 2 Diabetes Recruiting NCT03278704 Not Applicable
50 Effects of Foot Strengthening on the Incidence of Injuries in Long Distance Runners Recruiting NCT02306148 Not Applicable

Search NIH Clinical Center for Muscle Hypertrophy

Cochrane evidence based reviews: hypertrophy

Genetic Tests for Muscle Hypertrophy

Genetic tests related to Muscle Hypertrophy:

# Genetic test Affiliating Genes
1 Muscle Hypertrophy 29 MSTN

Anatomical Context for Muscle Hypertrophy

MalaCards organs/tissues related to Muscle Hypertrophy:

41
Skeletal Muscle, Smooth Muscle, Bone, Spinal Cord, Heart, Ovary, Prostate

Publications for Muscle Hypertrophy

Articles related to Muscle Hypertrophy:

(show top 50) (show all 236)
# Title Authors Year
1
Calf muscle hypertrophy following S1 radiculopathy: A stress disorder caused by hyperactivity with variable response to treatmen. ( 29451471 )
2018
2
Commentary: Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy. ( 29726548 )
2018
3
A mathematical model of the effects of resistance exercise-induced muscle hypertrophy on body composition. ( 29256047 )
2018
4
Non-osteogenic muscle hypertrophy in children with McArdle disease. ( 29594644 )
2018
5
Effect of 8-week leucine supplementation and resistance exercise training on muscle hypertrophy and satellite cell activation in rats. ( 29952091 )
2018
6
The development of skeletal muscle hypertrophy through resistance training: the role of muscle damage and muscle protein synthesis. ( 29282529 )
2018
7
Recent Perspectives Regarding the Role of Dietary Protein for the Promotion of Muscle Hypertrophy with Resistance Exercise Training. ( 29414855 )
2018
8
Titin-based mechanosensing modulates muscle hypertrophy. ( 29978560 )
2018
9
Isolated unilateral temporalis muscle hypertrophy in a child: a case report with literature review. ( 29458353 )
2018
10
Effects of contraction mode and stimulation frequency on electrical stimulation-induced skeletal muscle hypertrophy. ( 29074713 )
2018
11
Incorporation of a skeletal muscle-specific enhancer in the regulatory region of Igf1 upregulates IGF1 expression and induces skeletal muscle hypertrophy. ( 29426944 )
2018
12
Biomarkers associated with low, moderate, and high vastus lateralis muscle hypertrophy following 12 weeks of resistance training. ( 29621305 )
2018
13
Muscle hypertrophy following blood flow-restricted low force isometric electrical stimulation in rat tibialis anterior: Role for muscle hypoxia. ( 29565774 )
2018
14
Potential Roles of Vascular Endothelial Growth Factor During Skeletal Muscle Hypertrophy. ( 29652692 )
2018
15
The role of hormones in muscle hypertrophy. ( 29172848 )
2018
16
Coffee consumption promotes skeletal muscle hypertrophy and myoblast differentiation. ( 29359224 )
2018
17
I^-Secretase Inhibition Induces Muscle Hypertrophy in a Notch-Independent Mechanism. ( 29280566 )
2018
18
Akt1 deficiency diminishes skeletal muscle hypertrophy by reducing satellite cell proliferation. ( 29443546 )
2018
19
Correction to: A mathematical model of the effects of resistance exercise-induced muscle hypertrophy on body composition. ( 29948197 )
2018
20
Comment on: Volume for Muscle Hypertrophy and Health Outcomes: The Most Effective Variable in Resistance Training. ( 29396783 )
2018
21
Author's Reply to Souza et al: Comment on: "Volume for Muscle Hypertrophy and Health Outcomes: The Most Effective Variable in Resistance Training". ( 29396782 )
2018
22
An FBXO40 knockout generated by CRISPR/Cas9 causes muscle hypertrophy in pigs without detectable pathological effects. ( 29545179 )
2018
23
New Management in Bilateral Masseter Muscle Hypertrophy. ( 29109846 )
2017
24
Differential requirement for satellite cells during overload-induced muscle hypertrophy in growing versus mature mice. ( 28693603 )
2017
25
Myotonia in a Child with Muscle Hypertrophy. ( 28141569 )
2017
26
Muscle hypertrophy in hypoxia with inflammation is controlled by bromodomain and extra-terminal domain proteins. ( 28935884 )
2017
27
Comparative Proteomic and Transcriptomic Analysis of Follistatin-Induced Skeletal Muscle Hypertrophy. ( 28810121 )
2017
28
Creatine supplementation elicits greater muscle hypertrophy in upper than lower limbs and trunk in resistance-trained men. ( 29214923 )
2017
29
Glucocorticoid Receptor ChIP-Seq Identifies PLCD1 as a KLF15 Target that Represses Airway Smooth Muscle Hypertrophy. ( 28375666 )
2017
30
The effects of short versus long inter-set rest intervals in resistance training on measures of muscle hypertrophy: A systematic review. ( 28641044 )
2017
31
Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy. ( 29109273 )
2017
32
Total training load may explain similar strength gains and muscle hypertrophy seen in aged rats submitted to resistance training and anabolic steroids. ( 28817355 )
2017
33
Effects of Light-Emitting Diode Therapy on Muscle Hypertrophy, Gene Expression, Performance, Damage, and Delayed-Onset Muscle Soreness: A Case-Control Study With a Pair of Identical Twins. ( 28665818 )
2017
34
Comparative Analysis of Muscle Hypertrophy Models Reveals Divergent Gene Transcription Profiles and Points to Translational Regulation of Muscle Growth through Increased mTOR Signaling. ( 29255421 )
2017
35
Significance of isolated papillary muscle hypertrophy: A comparison of left ventricular hypertrophy diagnosed using electrocardiography vs echocardiography. ( 29280520 )
2017
36
Satellite Cells Contribution to Exercise Mediated Muscle Hypertrophy and Repair. ( 28042532 )
2017
37
Irisin is a pro-myogenic factor that induces skeletal muscle hypertrophy and rescues denervation-induced atrophy. ( 29062100 )
2017
38
Apigenin enhances skeletal muscle hypertrophy and myoblast differentiation by regulating Prmt7. ( 29108230 )
2017
39
Muscle hypertrophy and pseudohypertrophy. ( 28778933 )
2017
40
Androgen interacts with exercise through the mTOR pathway to induce skeletal muscle hypertrophy. ( 29472733 )
2017
41
Strength Training with Repetitions to Failure does not Provide Additional Strength and Muscle Hypertrophy Gains in Young Women. ( 28713535 )
2017
42
Reply to the Letter to the Editor on "Effects of Light-Emitting Diode Therapy on Muscle Hypertrophy, Gene Expression, Performance, Damage, and Delayed-Onset Muscle Soreness: Case-Control Study With a Pair of Identical Twins". ( 28644245 )
2017
43
Moderate Intensity Cycling Exercise after Upper Extremity Resistance Training Interferes Response to Muscle Hypertrophy but Not Strength Gains. ( 28912657 )
2017
44
lncRNA Chronos is an aging-induced inhibitor of muscle hypertrophy. ( 28855249 )
2017
45
Defining the STATus quo in muscle hypertrophy. Focus on "Overload-mediated skeletal muscle hypertrophy is not impaired by loss of myofiber STAT3". ( 28768642 )
2017
46
Low-load bench press and push-up induce similar muscle hypertrophy and strength gain. ( 29541130 )
2017
47
Myogenic Progenitor Cells Control Extracellular Matrix Production by Fibroblasts during Skeletal Muscle Hypertrophy. ( 27840022 )
2017
48
Relationship between Dietary Protein or Essential Amino Acid Intake and Training-Induced Muscle Hypertrophy among Older Individuals. ( 29332899 )
2017
49
Teaching Video NeuroImages: Trapezius muscle hypertrophy in multifocal motor neuropathy. ( 28808176 )
2017
50
Can low-load blood-flow restriction training elicit muscle hypertrophy with modest inflammation and cellular stress, but minimal muscle damage? ( 28949007 )
2017

Variations for Muscle Hypertrophy

ClinVar genetic disease variations for Muscle Hypertrophy:

6
(show top 50) (show all 64)
# Gene Variation Type Significance SNP ID Assembly Location
1 MSTN NM_005259.2(MSTN): c.373+5G> A single nucleotide variant Pathogenic rs397515373 GRCh37 Chromosome 2, 190926945: 190926945
2 MSTN NM_005259.2(MSTN): c.373+5G> A single nucleotide variant Pathogenic rs397515373 GRCh38 Chromosome 2, 190062219: 190062219
3 MSTN NM_005259.2(MSTN): c.*493G> A single nucleotide variant Benign rs16832285 GRCh38 Chromosome 2, 190056765: 190056765
4 MSTN NM_005259.2(MSTN): c.*290C> T single nucleotide variant Likely benign rs537956645 GRCh38 Chromosome 2, 190056968: 190056968
5 MSTN NM_005259.2(MSTN): c.*290C> T single nucleotide variant Likely benign rs537956645 GRCh37 Chromosome 2, 190921694: 190921694
6 MSTN NM_005259.2(MSTN): c.*1332A> G single nucleotide variant Benign rs3791782 GRCh38 Chromosome 2, 190055926: 190055926
7 MSTN NM_005259.2(MSTN): c.*1332A> G single nucleotide variant Benign rs3791782 GRCh37 Chromosome 2, 190920652: 190920652
8 MSTN NM_005259.2(MSTN): c.1062T> C (p.Asn354=) single nucleotide variant Uncertain significance rs761053215 GRCh37 Chromosome 2, 190922050: 190922050
9 MSTN NM_005259.2(MSTN): c.1062T> C (p.Asn354=) single nucleotide variant Uncertain significance rs761053215 GRCh38 Chromosome 2, 190057324: 190057324
10 MSTN NM_005259.2(MSTN): c.386T> G (p.Met129Arg) single nucleotide variant Likely benign rs142195885 GRCh37 Chromosome 2, 190925149: 190925149
11 MSTN NM_005259.2(MSTN): c.386T> G (p.Met129Arg) single nucleotide variant Likely benign rs142195885 GRCh38 Chromosome 2, 190060423: 190060423
12 MSTN NM_005259.2(MSTN): c.306C> T (p.Ser102=) single nucleotide variant Likely benign rs34191156 GRCh37 Chromosome 2, 190927017: 190927017
13 MSTN NM_005259.2(MSTN): c.306C> T (p.Ser102=) single nucleotide variant Likely benign rs34191156 GRCh38 Chromosome 2, 190062291: 190062291
14 MSTN NM_005259.2(MSTN): c.263G> A (p.Arg88Gln) single nucleotide variant Likely benign rs138343163 GRCh37 Chromosome 2, 190927060: 190927060
15 MSTN NM_005259.2(MSTN): c.263G> A (p.Arg88Gln) single nucleotide variant Likely benign rs138343163 GRCh38 Chromosome 2, 190062334: 190062334
16 MSTN NM_005259.2(MSTN): c.-41_-39delGAA deletion Likely benign rs772646099 GRCh37 Chromosome 2, 190927361: 190927363
17 MSTN NM_005259.2(MSTN): c.-41_-39delGAA deletion Likely benign rs772646099 GRCh38 Chromosome 2, 190062635: 190062637
18 MSTN NM_005259.2(MSTN): c.*1450T> C single nucleotide variant Likely benign rs144167726 GRCh38 Chromosome 2, 190055808: 190055808
19 MSTN NM_005259.2(MSTN): c.*1450T> C single nucleotide variant Likely benign rs144167726 GRCh37 Chromosome 2, 190920534: 190920534
20 MSTN NM_005259.2(MSTN): c.*1073G> T single nucleotide variant Uncertain significance rs886055370 GRCh38 Chromosome 2, 190056185: 190056185
21 MSTN NM_005259.2(MSTN): c.*1073G> T single nucleotide variant Uncertain significance rs886055370 GRCh37 Chromosome 2, 190920911: 190920911
22 MSTN NM_005259.2(MSTN): c.*923T> C single nucleotide variant Uncertain significance rs886055371 GRCh38 Chromosome 2, 190056335: 190056335
23 MSTN NM_005259.2(MSTN): c.*923T> C single nucleotide variant Uncertain significance rs886055371 GRCh37 Chromosome 2, 190921061: 190921061
24 MSTN NM_005259.2(MSTN): c.*574G> A single nucleotide variant Likely benign rs114597606 GRCh38 Chromosome 2, 190056684: 190056684
25 MSTN NM_005259.2(MSTN): c.*574G> A single nucleotide variant Likely benign rs114597606 GRCh37 Chromosome 2, 190921410: 190921410
26 MSTN NM_005259.2(MSTN): c.*395A> C single nucleotide variant Benign rs16823986 GRCh38 Chromosome 2, 190056863: 190056863
27 MSTN NM_005259.2(MSTN): c.*395A> C single nucleotide variant Benign rs16823986 GRCh37 Chromosome 2, 190921589: 190921589
28 MSTN NM_005259.2(MSTN): c.*259A> G single nucleotide variant Likely benign rs578136956 GRCh38 Chromosome 2, 190056999: 190056999
29 MSTN NM_005259.2(MSTN): c.*259A> G single nucleotide variant Likely benign rs578136956 GRCh37 Chromosome 2, 190921725: 190921725
30 MSTN NM_005259.2(MSTN): c.748-3C> T single nucleotide variant Uncertain significance rs374256136 GRCh37 Chromosome 2, 190922367: 190922367
31 MSTN NM_005259.2(MSTN): c.748-3C> T single nucleotide variant Uncertain significance rs374256136 GRCh38 Chromosome 2, 190057641: 190057641
32 MSTN NM_005259.2(MSTN): c.551C> T (p.Thr184Ile) single nucleotide variant Uncertain significance rs369290669 GRCh37 Chromosome 2, 190924984: 190924984
33 MSTN NM_005259.2(MSTN): c.551C> T (p.Thr184Ile) single nucleotide variant Uncertain significance rs369290669 GRCh38 Chromosome 2, 190060258: 190060258
34 MSTN NM_005259.2(MSTN): c.466C> A (p.Leu156Ile) single nucleotide variant Likely benign rs35493945 GRCh37 Chromosome 2, 190925069: 190925069
35 MSTN NM_005259.2(MSTN): c.466C> A (p.Leu156Ile) single nucleotide variant Likely benign rs35493945 GRCh38 Chromosome 2, 190060343: 190060343
36 MSTN NM_005259.2(MSTN): c.-17A> C single nucleotide variant Uncertain significance rs201887141 GRCh37 Chromosome 2, 190927339: 190927339
37 MSTN NM_005259.2(MSTN): c.-17A> C single nucleotide variant Uncertain significance rs201887141 GRCh38 Chromosome 2, 190062613: 190062613
38 MSTN NM_005259.2(MSTN): c.*1362A> G single nucleotide variant Likely benign rs377503267 GRCh37 Chromosome 2, 190920622: 190920622
39 MSTN NM_005259.2(MSTN): c.*697T> C single nucleotide variant Likely benign rs186458339 GRCh37 Chromosome 2, 190921287: 190921287
40 MSTN NM_005259.2(MSTN): c.*493G> A single nucleotide variant Benign rs16832285 GRCh37 Chromosome 2, 190921491: 190921491
41 MSTN NM_005259.2(MSTN): c.*1362A> G single nucleotide variant Likely benign rs377503267 GRCh38 Chromosome 2, 190055896: 190055896
42 MSTN NM_005259.2(MSTN): c.*697T> C single nucleotide variant Likely benign rs186458339 GRCh38 Chromosome 2, 190056561: 190056561
43 MSTN NM_005259.2(MSTN): c.*135G> A single nucleotide variant Benign rs60490864 GRCh38 Chromosome 2, 190057123: 190057123
44 MSTN NM_005259.2(MSTN): c.*135G> A single nucleotide variant Benign rs60490864 GRCh37 Chromosome 2, 190921849: 190921849
45 MSTN NM_005259.2(MSTN): c.*121A> G single nucleotide variant Uncertain significance rs886055372 GRCh37 Chromosome 2, 190921863: 190921863
46 MSTN NM_005259.2(MSTN): c.*121A> G single nucleotide variant Uncertain significance rs886055372 GRCh38 Chromosome 2, 190057137: 190057137
47 MSTN NM_005259.2(MSTN): c.674T> C (p.Ile225Thr) single nucleotide variant Likely benign rs143242500 GRCh37 Chromosome 2, 190924861: 190924861
48 MSTN NM_005259.2(MSTN): c.674T> C (p.Ile225Thr) single nucleotide variant Likely benign rs143242500 GRCh38 Chromosome 2, 190060135: 190060135
49 MSTN NM_005259.2(MSTN): c.*1514C> G single nucleotide variant Benign rs12105165 GRCh38 Chromosome 2, 190055744: 190055744
50 MSTN NM_005259.2(MSTN): c.*1514C> G single nucleotide variant Benign rs12105165 GRCh37 Chromosome 2, 190920470: 190920470

Expression for Muscle Hypertrophy

Search GEO for disease gene expression data for Muscle Hypertrophy.

Pathways for Muscle Hypertrophy

Pathways related to Muscle Hypertrophy according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.7 AGT EDN1 IGF1 MEF2A MTOR
2
Show member pathways
12.25 FOXO1 HDAC4 IGF1 LEP MTOR
3
Show member pathways
11.94 HDAC4 IGF1 MEF2A MTOR
4
Show member pathways
11.92 FBXO32 FOXO1 IGF1 SMAD4
5 11.82 FOXO1 MTOR MYH6 SLC9A1
6 11.81 FOXO1 IGF1 MTOR
7 11.79 HDAC4 MEF2A MTOR SLC9A1 SMAD4
8 11.78 IGF1 MTOR SMAD4
9 11.73 EDN1 FOXO1 SMAD4
10 11.71 FOXO1 MTOR SMAD4
11 11.67 EDN1 IGF1 MTOR NPPA
12 11.6 MYH6 MYH7 SLC9A1
13 11.55 AGT FOXO1 IGF1 KLF15 LEP MEF2A
14 11.51 EDN1 LEP SMAD4
15
Show member pathways
11.37 AGT EDN1 HDAC4 IGF1 MEF2A MTOR
16 11.36 IGF1 MYH6 MYH7 SLC9A1
17
Show member pathways
11 EDN1 IGF1 MTOR
18 10.95 FBXO32 IGF1 MSTN MTOR
19 10.84 MYH7 NPPA SMAD4

GO Terms for Muscle Hypertrophy

Cellular components related to Muscle Hypertrophy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.53 AGT EDN1 FBXO32 FHL1 FOXO1 HDAC4
2 sarcomere GO:0030017 9.33 HDAC4 MYH6 MYH7
3 Z disc GO:0030018 9.26 FBXO32 HDAC4 MYH6 MYH7

Biological processes related to Muscle Hypertrophy according to GeneCards Suite gene sharing:

(show all 46)
# Name GO ID Score Top Affiliating Genes
1 in utero embryonic development GO:0001701 9.94 EDN1 GATA6 MYH6 SMAD4
2 response to hypoxia GO:0001666 9.93 EDN1 LEP NPPA SMAD4
3 glucose homeostasis GO:0042593 9.87 FOXO1 IGF1 LEP
4 negative regulation of cell growth GO:0030308 9.87 AGT FHL1 NPPA SMAD4
5 cellular response to hypoxia GO:0071456 9.86 EDN1 GATA6 MTOR SLC9A1
6 female pregnancy GO:0007565 9.85 AGT LEP NPPA
7 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.84 AGT IGF1 MTOR
8 muscle organ development GO:0007517 9.84 FHL1 IGF1 MEF2A MSTN
9 positive regulation of transcription, DNA-templated GO:0045893 9.81 AGT FOXO1 GATA6 HDAC4 IGF1 KLF15
10 cardiac muscle contraction GO:0060048 9.79 MTOR MYH6 MYH7
11 positive regulation of nitric oxide biosynthetic process GO:0045429 9.78 AGT EDN1 MTOR
12 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.78 AGT IGF1 LEP MYOC
13 response to activity GO:0014823 9.77 EDN1 LEP MTOR
14 cellular response to mechanical stimulus GO:0071260 9.77 AGT HDAC4 MTPN NPPA SLC9A1
15 regulation of heart rate GO:0002027 9.76 AGT MYH6 MYH7
16 cellular response to dexamethasone stimulus GO:0071549 9.75 FBXO32 FOXO1 MSTN
17 positive regulation of smooth muscle cell proliferation GO:0048661 9.73 EDN1 HDAC4 IGF1 MTOR
18 response to insulin GO:0032868 9.72 FOXO1 IGF1 LEP MTOR NPPA
19 positive regulation of insulin receptor signaling pathway GO:0046628 9.7 IGF1 LEP
20 regulation of stress fiber assembly GO:0051492 9.69 MYOC SLC9A1
21 cell growth involved in cardiac muscle cell development GO:0061049 9.69 AGT NPPA
22 regulation of blood vessel size GO:0050880 9.69 AGT EDN1 NPPA
23 energy reserve metabolic process GO:0006112 9.68 LEP MTOR
24 adult heart development GO:0007512 9.68 MYH6 MYH7
25 positive regulation of renal sodium excretion GO:0035815 9.68 AGT EDN1
26 positive regulation of calcineurin-NFAT signaling cascade GO:0070886 9.68 IGF1 SLC9A1
27 response to muscle stretch GO:0035994 9.67 EDN1 NPPA SLC9A1
28 response to denervation involved in regulation of muscle adaptation GO:0014894 9.66 FBXO32 HDAC4
29 artery smooth muscle contraction GO:0014824 9.66 AGT EDN1
30 response to transforming growth factor beta GO:0071559 9.65 EDN1 SMAD4
31 regulation of cardiac muscle contraction by calcium ion signaling GO:0010882 9.65 HDAC4 SLC9A1
32 cellular response to cold GO:0070417 9.65 FOXO1 SLC9A1
33 regulation of blood pressure GO:0008217 9.65 AGT EDN1 LEP MYH6 NPPA
34 negative regulation of smooth muscle cell apoptotic process GO:0034392 9.64 EDN1 IGF1
35 positive regulation of follicle-stimulating hormone secretion GO:0046881 9.63 LEP SMAD4
36 positive regulation of cell growth involved in cardiac muscle cell development GO:0061051 9.63 EDN1 IGF1 MTOR
37 bone mineralization involved in bone maturation GO:0035630 9.62 IGF1 LEP
38 regulation of brown fat cell differentiation GO:0090335 9.62 LEP MTOR
39 positive regulation of luteinizing hormone secretion GO:0033686 9.59 LEP SMAD4
40 positive regulation of cardiac muscle hypertrophy GO:0010613 9.43 AGT EDN1 IGF1 MEF2A MTPN SLC9A1
41 cardiac muscle hypertrophy in response to stress GO:0014898 9.1 GATA6 HDAC4 KLF15 MYH6 MYH7 NPPA
42 negative regulation of apoptotic process GO:0043066 10.09 FOXO1 GATA6 IGF1 LEP SLC9A1
43 negative regulation of transcription by RNA polymerase II GO:0000122 10.09 EDN1 FOXO1 GATA6 HDAC4 LEP MEF2A
44 positive regulation of cell proliferation GO:0008284 10.07 AGT EDN1 HDAC4 IGF1 LEP
45 positive regulation of transcription by RNA polymerase II GO:0045944 10.06 EDN1 FOXO1 GATA6 HDAC4 IGF1 KLF15
46 regulation of signaling receptor activity GO:0010469 10 AGT EDN1 IGF1 LEP MSTN NPPA

Molecular functions related to Muscle Hypertrophy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.8 GATA6 HDAC4 MEF2A MTOR MYH6
2 sequence-specific DNA binding GO:0043565 9.8 FOXO1 GATA6 HDAC4 MEF2A MTPN SMAD4
3 chromatin binding GO:0003682 9.77 FOXO1 GATA6 HDAC4 MEF2A SMAD4
4 transcription regulatory region DNA binding GO:0044212 9.55 GATA6 HDAC4 KLF15 MEF2A SMAD4
5 actin-dependent ATPase activity GO:0030898 9.46 MYH6 MYH7
6 peptide hormone receptor binding GO:0051428 9.43 LEP NPPA
7 RNA polymerase II transcription factor binding GO:0001085 9.26 GATA6 HDAC4 MEF2A SMAD4
8 hormone activity GO:0005179 9.02 AGT EDN1 IGF1 LEP NPPA
9 protein binding GO:0005515 10.21 AGT EDN1 FBXO32 FHL1 FOXO1 GATA6

Sources for Muscle Hypertrophy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....